The New England Journal of Medicine reported phase 3 trial details regarding the company's peanut allergy treatment for toddlers.
The company can now move forward with a late-stage study of its lead pipeline candidate.
March S&P 500 futures (ESH23) are trending up +0.17% this morning after three major U.S. benchmark indices closed sharply lower on Thursday, with the technology-heavy Nasdaq dropping the most after stronger-than-expected...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DBV Technologies S.A. (""DBV" or the "Company") (NASDAQ: DBVT). Such investors...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DBV Technologies S.A. (""DBV" or the "Company") (NASDAQ: DBVT). Such investors...
Montrouge, France, August 1, 2022 DBV Technologies Reports Second Quarter 2022 Financial Results DBV closes Q2 with a cash balance of $248M following...